Related Experiment Video
Updated: May 24, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Phosphate binder pill burden and cardiovascular events in patients undergoing hemodialysis
Kiryu Yoshida1, Tomohiro Saito2, Tadashi Kato2
1Division of Nephrology, Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Background:
Phosphate binders (PBs) are commonly prescribed to reduce serum phosphate levels. This study examined the association between the PB pill burden and cardiovascular events in hemodialysis patients.
Methods:
This retrospective cohort study included 395 patients undergoing hemodialysis between August 2018 and November 2023 at a single facility in Japan. Statistical analyses were conducted using baseline, time-averaged, and time-dependent Cox proportional hazard models.
Results:
Of the 395 included patients, cardiovascular events occurred in 121 patients (30.6%). The patients were categorized into tertiles based on their daily PB pill intake: T1 (<4 pills/day), T2 (4-8 pills/day), and T3 (≥9 pills/day). T3 was associated with increased cardiovascular risk (vs. T1 hazard ratio [HR] = 1.51, p = 0.064; vs. T2 HR = 2.06, p = 0.005). Similar results were obtained for the time-averaged and time-dependent models.
Conclusion:
A high PB pill burden (≥9/day) is associated with increased cardiovascular risk in patients undergoing hemodialysis.
Related Concept Videos
Heart Failure Drugs: Diuretics
Drug Distribution: Tissue Binding
For...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Antihypertensive Drugs: Action of Diuretics
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

